Second-Line Treatment for HR+, HER2- Metastatic Breast Cancer

Melissa Rikal, MSN, FNP-BC, AOCNP, shares strategies to help nurses improve adherence and patient education for oral oncolytic therapies.

Melissa Rikal, MSN, FNP-BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.

For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs treatment sequencing.

Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform next lines of therapy.

Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the prioritization of quality of life.

Using liquid biopsies to test for ESR1 mutations in breast cancer is more feasible for patients and has quicker turnaround times.

Katherine Cohen, MSN, FNP-C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

With newer breast cancer treatments, it’s essential that nurses and APPs educate themselves and advocate for their patients.

Advanced practice providers discuss the second-line use of elacestrant in patients with co-mutated, ER+, HER2—advanced or metastatic breast cancer

Testing for ESR1 mutations is essential after ER-positive HER2-negative breast cancer progressed.

Oral drugs in the HR-positive, HER2-negative metastatic breast cancer space put a focus on clear patient-provider communication about adherence and adverse events.

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in particular with the use of elacestrant, in HR-positive, HER2-negative metastatic breast cancer.

With several options available for the second-line treatment of HR-positive, HER2-negative mBC, an expert emphasized the importance of tailoring treatment for every patient.